Pharmalittle: We’re reading about a new policy for compounding peptides, a PBM disclosure rule, and more
Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for more than three decades. His stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation and legislation. He is…